BeOne Medicines AG declines as market weakens
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Should l Buy ONC?
Source: SeekingAlpha
BeOne Medicines AG's stock fell by 3.34% and hit a 20-day low amid a broader market decline, with the Nasdaq-100 down 0.24% and the S&P 500 down 0.63%.
This decline is attributed to broad market weakness, as the overall market sentiment shifted negatively, impacting many stocks in the biotechnology sector. The stock's movement reflects a sector rotation, where investors are reallocating their investments away from biotech amid current market conditions.
The implications of this decline suggest that BeOne Medicines AG may face continued pressure unless there are positive developments or shifts in market sentiment that could favor the biotechnology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 403.76 USD with a low forecast of 385.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 347.000
Low
385.00
Averages
403.76
High
424.00
Current: 347.000
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazon and BeOne Medicines Show Promising Prospects
- Amazon Earnings Growth: Amazon is expected to report robust earnings growth in its upcoming Q4 2025 results, driven by efficiency improvements, despite lagging behind the S&P 500 over the past 12 months.
- BeOne Drug Approvals: BeOne Medicines' flagship drug, Brukinsa, has become the gold standard for treating various blood cancers, and the recent Chinese regulatory approval for sonrotoclax is expected to boost sales in both the U.S. and Europe.
- Enterprise Products Partners Appeal: With a forward distribution yield of 6.6% and 27 consecutive years of dividend increases, Enterprise Products Partners is attractive for income investors, and the anticipated growth in natural gas demand from AI data center construction could enhance its market position.
- Investor Attention: Although Amazon was not included in the Motley Fool Stock Advisor's top investment picks, its AWS division is projected to benefit significantly from the widespread adoption of AI agents in 2026, potentially enhancing the company's competitive edge.
See More
February Investment Opportunities: Amazon and Three Stocks to Buy
- Amazon Earnings Growth: Amazon (AMZN) has lagged behind the S&P 500 over the past 12 months, but its fourth-quarter 2025 earnings are expected to show robust growth, potentially driving stock price recovery with a market cap of $2.6 trillion and a gross margin of 50.05%.
- BeOne Drug Approval: BeOne Medicines (ONC) has seen its stock soar over 50% in the past year, with its flagship product Brukinsa now the gold standard for blood cancer treatment, and sales are expected to continue rising in both the U.S. and Europe, giving it a market cap of $38 billion.
- New Drug Application Progress: BeOne recently received Chinese regulatory approval for sonrotoclax to treat relapsed/refractory (R/R) lymphoma and is poised to file for accelerated approval of BGB-16673 pending positive Phase 2 clinical results, which could further enhance its growth trajectory.
- Enterprise Products Partners Dividends: Enterprise Products Partners (EPD) offers a forward distribution yield of 6.6%, having increased its dividends for 27 consecutive years, and the anticipated boom in AI data center construction is expected to drive natural gas demand growth, enhancing its market performance.
See More
FDA Accepts Summit Therapeutics' BLA for Ivonescimab
- BLA Acceptance: The FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in combination with chemotherapy for EGFR-mutated advanced non-small cell lung cancer, with a decision expected by November 14, 2026.
- Clinical Trial Results: The Phase 3 HARMONi trial showed a median overall survival of 16.8 months for ivonescimab plus chemotherapy compared to 14.1 months for chemotherapy alone, indicating significant therapeutic potential.
- Future Research Plans: Summit anticipates completing enrollment in the squamous cohort of the HARMONi-3 trial in the first half of 2026, with primary endpoint analysis expected in the second half of 2026, further advancing ivonescimab's clinical development.
- New Study Initiation: The company has initiated the Phase 3 HARMONi-GI3 study for first-line unresectable metastatic colorectal cancer, aiming to expand ivonescimab's clinical development program to meet market needs.
See More
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
- Market Volatility: On Wednesday, the S&P 500 and Dow reversed from their highs, indicating a shift in market sentiment that could influence short-term investor decisions.
- Nasdaq Performance: Although the Nasdaq index initially gained, it ultimately narrowed its gains, reflecting the volatility of tech stocks and the uncertainty in the market.
- Buy Signals: Eli Lilly and Google flashed buy signals, potentially attracting investor interest in these companies' future growth prospects, especially in the current market environment.
- Investor Sentiment: The overall market reversal may lead investors to reassess their risk appetite, thereby affecting capital flows and market dynamics.
See More
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
- Market Volatility: On Wednesday, the S&P 500 and Dow retreated from their highs, indicating a shift in market sentiment that could influence short-term investor decisions and risk appetite.
- Nasdaq Performance: Although the Nasdaq index pared gains, it still shows potential for growth, suggesting that volatility in tech stocks may provide short-term trading opportunities for investors.
- Buy Signals: Stocks of Eli Lilly and Google flashed buy signals, potentially attracting investor attention to the growth prospects of these companies in their respective sectors, which could drive their stock prices higher.
- Investor Strategy Adjustment: The market fluctuations and buy signals may prompt investors to reassess their portfolios, particularly in the current economic environment, seeking more promising investment opportunities.
See More
Jazz Pharmaceuticals Reports Ziihera Trial Shows Significant Survival Benefits
- Clinical Trial Results: Jazz Pharmaceuticals' Phase 3 HERIZON-GEA-01 trial demonstrated that the doublet therapy of Ziihera plus chemotherapy improved progression-free survival (PFS) by 35%, while the triplet therapy reduced the risk of disease progression or death by approximately 37%, indicating significant clinical relevance.
- Survival Improvement: The triplet therapy achieved a median overall survival (OS) of over two years (26.4 months), marking the longest reported in a Phase 3 trial for GEA, representing more than a seven-month improvement compared to the control arm, thus providing substantial benefits to patients.
- Statistical Trends: The doublet therapy showed a median OS of 24.4 months, with a preliminary trend towards a 20% reduction in death risk, although not statistically significant (p-value of 0.0564), suggesting its potential clinical value.
- Future Analysis Plans: Jazz Pharmaceuticals plans an additional OS interim analysis for Ziihera plus chemotherapy in mid-2026, which may further validate its efficacy and safety, potentially offering new treatment options in the market.
See More
Amazon and BeOne Medicines Show Promising Prospects
- Amazon Earnings Growth: Amazon is expected to report robust earnings growth in its upcoming Q4 2025 results, driven by efficiency improvements, despite lagging behind the S&P 500 over the past 12 months.
- BeOne Drug Approvals: BeOne Medicines' flagship drug, Brukinsa, has become the gold standard for treating various blood cancers, and the recent Chinese regulatory approval for sonrotoclax is expected to boost sales in both the U.S. and Europe.
- Enterprise Products Partners Appeal: With a forward distribution yield of 6.6% and 27 consecutive years of dividend increases, Enterprise Products Partners is attractive for income investors, and the anticipated growth in natural gas demand from AI data center construction could enhance its market position.
- Investor Attention: Although Amazon was not included in the Motley Fool Stock Advisor's top investment picks, its AWS division is projected to benefit significantly from the widespread adoption of AI agents in 2026, potentially enhancing the company's competitive edge.
See More
February Investment Opportunities: Amazon and Three Stocks to Buy
- Amazon Earnings Growth: Amazon (AMZN) has lagged behind the S&P 500 over the past 12 months, but its fourth-quarter 2025 earnings are expected to show robust growth, potentially driving stock price recovery with a market cap of $2.6 trillion and a gross margin of 50.05%.
- BeOne Drug Approval: BeOne Medicines (ONC) has seen its stock soar over 50% in the past year, with its flagship product Brukinsa now the gold standard for blood cancer treatment, and sales are expected to continue rising in both the U.S. and Europe, giving it a market cap of $38 billion.
- New Drug Application Progress: BeOne recently received Chinese regulatory approval for sonrotoclax to treat relapsed/refractory (R/R) lymphoma and is poised to file for accelerated approval of BGB-16673 pending positive Phase 2 clinical results, which could further enhance its growth trajectory.
- Enterprise Products Partners Dividends: Enterprise Products Partners (EPD) offers a forward distribution yield of 6.6%, having increased its dividends for 27 consecutive years, and the anticipated boom in AI data center construction is expected to drive natural gas demand growth, enhancing its market performance.
See More
FDA Accepts Summit Therapeutics' BLA for Ivonescimab
- BLA Acceptance: The FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in combination with chemotherapy for EGFR-mutated advanced non-small cell lung cancer, with a decision expected by November 14, 2026.
- Clinical Trial Results: The Phase 3 HARMONi trial showed a median overall survival of 16.8 months for ivonescimab plus chemotherapy compared to 14.1 months for chemotherapy alone, indicating significant therapeutic potential.
- Future Research Plans: Summit anticipates completing enrollment in the squamous cohort of the HARMONi-3 trial in the first half of 2026, with primary endpoint analysis expected in the second half of 2026, further advancing ivonescimab's clinical development.
- New Study Initiation: The company has initiated the Phase 3 HARMONi-GI3 study for first-line unresectable metastatic colorectal cancer, aiming to expand ivonescimab's clinical development program to meet market needs.
See More
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
- Market Volatility: On Wednesday, the S&P 500 and Dow reversed from their highs, indicating a shift in market sentiment that could influence short-term investor decisions.
- Nasdaq Performance: Although the Nasdaq index initially gained, it ultimately narrowed its gains, reflecting the volatility of tech stocks and the uncertainty in the market.
- Buy Signals: Eli Lilly and Google flashed buy signals, potentially attracting investor interest in these companies' future growth prospects, especially in the current market environment.
- Investor Sentiment: The overall market reversal may lead investors to reassess their risk appetite, thereby affecting capital flows and market dynamics.
See More
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
- Market Volatility: On Wednesday, the S&P 500 and Dow retreated from their highs, indicating a shift in market sentiment that could influence short-term investor decisions and risk appetite.
- Nasdaq Performance: Although the Nasdaq index pared gains, it still shows potential for growth, suggesting that volatility in tech stocks may provide short-term trading opportunities for investors.
- Buy Signals: Stocks of Eli Lilly and Google flashed buy signals, potentially attracting investor attention to the growth prospects of these companies in their respective sectors, which could drive their stock prices higher.
- Investor Strategy Adjustment: The market fluctuations and buy signals may prompt investors to reassess their portfolios, particularly in the current economic environment, seeking more promising investment opportunities.
See More
Jazz Pharmaceuticals Reports Ziihera Trial Shows Significant Survival Benefits
- Clinical Trial Results: Jazz Pharmaceuticals' Phase 3 HERIZON-GEA-01 trial demonstrated that the doublet therapy of Ziihera plus chemotherapy improved progression-free survival (PFS) by 35%, while the triplet therapy reduced the risk of disease progression or death by approximately 37%, indicating significant clinical relevance.
- Survival Improvement: The triplet therapy achieved a median overall survival (OS) of over two years (26.4 months), marking the longest reported in a Phase 3 trial for GEA, representing more than a seven-month improvement compared to the control arm, thus providing substantial benefits to patients.
- Statistical Trends: The doublet therapy showed a median OS of 24.4 months, with a preliminary trend towards a 20% reduction in death risk, although not statistically significant (p-value of 0.0564), suggesting its potential clinical value.
- Future Analysis Plans: Jazz Pharmaceuticals plans an additional OS interim analysis for Ziihera plus chemotherapy in mid-2026, which may further validate its efficacy and safety, potentially offering new treatment options in the market.
See More
